12,372 trials
Progressive Cognitive Decline
Primary: Percentage of Subjects Who Undergo a Hypothetical Change in Clinical Diagnosis and Physician Management Plan After Obtaining a Negative Florbetapir F 18 PET Scan…
Hypertension
Primary: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) — -8.7; -3.6 mmHg — p=<.001
Atrial Fibrillation
Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95
Diabetes Mellitus
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 87.2; 87.1; 84.6; 25.6 percentage of participants
Influenza
Primary: Immunogenicity - Geometric Mean Titer Fold Increase From Baseline — 3.5; 4.0; 4.5; 3.4 GMT fold increase
Depression
Primary: Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher — 32; 59 percentage of participants
Heterozygous Familial Hypercholesterolemia · Coronary Artery Disease
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — 5.17; -28.02 percentage of Baseline — p=<0.001
Lipid Metabolism, Inborn Errors · Hypercholesterolemia, Autosomal Dominant · Hyperlipidemias
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point — -3.31; -24.66 percentage of baseline — p=<0.001
Prostate Cancer
Primary: Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight — 3; 6; 3; 6 participants
Hypercholesterolemia · Coronary Heart Disease
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point — 12.5; -35.9 percentage of baseline — p=<0.001
Primary Immune Deficiency
Primary: IgG Trough Level — 1.09; 1.11 Ratio of Geometric Means
COPD
Primary: Exercise Tolerance Comparison Between QVA149 and Placebo Groups — 507.8; 448.3 Seconds
Hypercholesterolemia · Coronary Heart Disease
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — -3.4; -40.2 percentage of baseline — p=<0.001
Migraine Disorders
Primary: Subject Self-examination of Skin Irritation — 0.6 scores on a scale
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease. — 21.6; 24.9; 22.1; 12.3 titers